Zeitliche Entwicklung der Anwendungsprävalenz von Statinen in Deutschland – Ergebnisse der nationalen Interview- und Untersuchungssurveys 1997-1999 und 2008-2011-Reference-Cited by-同舟云学术

Zeitliche Entwicklung der Anwendungsprävalenz von Statinen in Deutschland – Ergebnisse der nationalen Interview- und Untersuchungssurveys 1997-1999 und 2008-2011

Published:2017-05 Issue: Volume:122 Page:22-31
ISSN:1865-9217
Container-title:Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
language:de
Short-container-title:Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen

Author:

Knopf Hildtraud C.,Busch Markus A.,Du Yong,Truthmann Julia,Schienkiewitz Anja,Scheidt-Nave Christa

Publisher

Elsevier BV

Subject

Medicine (miscellaneous),Health Policy,Education

Reference60 articles.

1. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

2. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study;Yusuf;Lancet,2004

3. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study;Velagaleti;Circulation,2009

4. Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997-99 and 2008-11;Truthmann;BMC Public Health.,2016

5. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Goff;Circulation,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond;International Journal of Molecular Sciences;2022-01-19

2. Utilisation patterns and costs of lipid-lowering drugs in Switzerland 2013–2019;Swiss Medical Weekly;2021-08-30

3. Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity;Cells;2021-06-29

4. Prevalence and predictors of statin therapy in the general working-age population;Russian Journal of Cardiology;2020-07-11

5. Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population‐based registry in southwest Germany;European Journal of Neurology;2020-06-02